Navigation Links
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

8, and approximately 28,660 men are expected to die this year from the disease(1). Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases of the central nervous system and cancers for which there are limited treatment options. Medivation aims to revolutionize the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial of Dimebon in patients with mild-to-moderate Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review proce
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...o take body temperature, for home,and clinical use...- Kidz-Med, Inc.,(subsidiary of American Scientifi... distributor of the Thermofocus(R) 5-in-1 non-cont...s of a clinical study,conducted by the Second Chil..., Italy, which proves that the Thermofocus(R) meas...
(Date:7/23/2008)... Therapy to Treat the Disease -, WAYNE, N.J. and ... --,Bayer HealthCare Pharmaceuticals and Onyx Phar...hat The New England Journal of Medicine published,...var(R) (sorafenib),tablets decreased the absolute ...ectable hepatocellular carcinoma (HCC), or liver c...
(Date:7/23/2008)...wswire/ -- The following was,released by the U.S. ... Member Smith, and Members of the Committee.,Thank... I appeared before this Committee almost six month...he talented and dedicated professionals,at the Jus...ave come to,appreciate that much more deeply their...
(Date:7/23/2008)...-- InCode BioPharmaceutics, Inc.,an emerging biop... test,results demonstrating the utility of their l...rare chronic blood disorder paroxysmal nocturnal,h...presented at the XXII,International Complement Wor... The only treatment currently available for PNH pa...
Breaking Medicine Technology:Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 1Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 3Immune Design Announces 2418 Million Series A Financing 22475 1Immune Design Announces 2418 Million Series A Financing 22475 2Immune Design Announces 2418 Million Series A Financing 22475 3John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 1John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 2Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 1Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 2
...tionality in Humans of CTI,s,Programmable, Pulsati...onoDose, BASEL, Switzerland and TRENTON, N.J., May... (CTI) announced today the successful,completion o...rammable, pulsatile, passive transdermal drug/devi...s to publish this,clinical data in leading scienti...
...IRE)--May 7, 2007 - NanoViricides,Inc. (Pink Shee...es,against rabies and BSL3 in vitro studies agains...rd Annual Symposium of the Pan,American Society fo...y 2. (Pan American Society for Clinical Virology (...dies against Clade 2 H5N1, a Dec. 2006 isolate in,...
Other Medicine Technology:Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus 2
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...the risk of heart disease, but now researchers say...r the development of a heart attack.This is becaus... almost immediate impact on the cardiovascular sys...ents, the researchers found that those who smoked ...
...chool of Medicine have recently found that the bra...hat lets us stop smelling something, even though t... recent issue of the journal Science show that a p...‘nose’ of odour receptor cells.//The main job of t...
...inking could reduce their risk of suffering a stro.... In a new leaflet, the Stroke Association says sm...ic strokes - caused by blood clots blocking arteri...es of the brain attack.// Alcohol thins the blood...
...he South Sea Islands. It is a herb that has been i...ses. The herb is commonly used by consumers as a g...ress and muscle spasms. According to experts, the ...wn as// benzodiazepines but is not chemically rela...
Other Medicine News:
The Sphincter of Oddi Manometry Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID multiparametric recorder to record and analyze pressure signals from sphincter of Oddi man
...rise the SmartPill GI Monitoring System., ,Three ...toring System: SmartPill pH.p Capsule software, Sm...iGI software. These three components are integrate...toring System and function together with system ha...
... NET™ (PNET) works with the Polygraf™ ...pressure signals from continuous pull-through proc...cter (LES)., ,Continuous pull-through procedures ...r Puller, but they may be carried out manually wit...
... POLYGRAM NET™ works with the Polygraf&trade...e multichannel EGG signals. The EGG analysis takes...ng an automatic electrode impedance check on every...ording. If the electrode impedance is measured abo...
Medicine Products: